Literature DB >> 1309242

Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes.

M Rowe1, A L Lear, D Croom-Carter, A H Davies, A B Rickinson.   

Abstract

Previous studies on Epstein-Barr virus (EBV)-positive B-cell lines have identified two distinct forms of virus latency. Lymphoblastoid cell lines generated by virus-induced transformation of normal B cells in vitro, express the full spectrum of six EBNAs and three latent membrane proteins (LMP1, LMP2A, and LMP2B); furthermore, these lines often contain a small fraction of cells spontaneously entering the lytic cycle. In contrast, Burkitt's lymphoma-derived cell lines retaining the tumor biopsy cell phenotype express only one of the latent proteins, the nuclear antigen EBNA1; such cells do not enter the lytic cycle spontaneously but may be induced to do so by treatment with such agents as tetradecanoyl phorbol acetate and anti-immunoglobulin. The present study set out to determine whether activation of full virus latent-gene expression was a necessary accompaniment to induction of the lytic cycle in Burkitt's lymphoma lines. Detailed analysis of Burkitt's lymphoma lines responding to anti-immunoglobulin treatment revealed three response pathways of EBV gene activation from EBNA1-positive latency. A first, rapid response pathway involves direct entry of cells into the lytic cycle without broadening of the pattern of latent gene expression; thereafter, the three "latent" LMPs are expressed as early lytic cycle antigens. A second, delayed response pathway in another cell subpopulation involves the activation of full latent gene expression and conversion to a lymphoblastoidlike cell phenotype. A third response pathway in yet another subpopulation involves the selective activation of LMPs, with no induction of the lytic cycle and with EBNA expression still restricted to EBNA1; this type of latent infection in B lymphocytes has hitherto not been described. Interestingly, the EBNA1+ LMP+ cells displayed some but not all of the phenotypic changes normally induced by LMP1 expression in a B-cell environment. These studies highlight the existence of four different types of EBV infection in B cells, including three distinct forms of latency, which we now term latency I, latency II, and latency III.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1309242      PMCID: PMC238267     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  55 in total

1.  Monoclonal antibodies to the latent membrane protein of Epstein-Barr virus reveal heterogeneity of the protein and inducible expression in virus-transformed cells.

Authors:  M Rowe; H S Evans; L S Young; K Hennessy; E Kieff; A B Rickinson
Journal:  J Gen Virol       Date:  1987-06       Impact factor: 3.891

2.  Epstein-Barr virus-encoded nuclear antigen 2 activates the viral latent membrane protein promoter by modulating the activity of a negative regulatory element.

Authors:  R Fåhraeus; A Jansson; A Ricksten; A Sjöblom; L Rymo
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

3.  Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line.

Authors:  C D Gregory; M Rowe; A B Rickinson
Journal:  J Gen Virol       Date:  1990-07       Impact factor: 3.891

4.  Persisting oncogenic herpesvirus induced by the tumour promotor TPA.

Authors:  H zur Hausen; F J O'Neill; U K Freese; E Hecker
Journal:  Nature       Date:  1978-03-23       Impact factor: 49.962

5.  Synchronous and sequential activation of latently infected Epstein-Barr virus genomes.

Authors:  K Takada; Y Ono
Journal:  J Virol       Date:  1989-01       Impact factor: 5.103

6.  Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation.

Authors:  F Pezzella; A G Tse; J L Cordell; K A Pulford; K C Gatter; D Y Mason
Journal:  Am J Pathol       Date:  1990-08       Impact factor: 4.307

7.  Up regulation of the Epstein-Barr virus (EBV)-encoded membrane protein LMP in the Burkitt's lymphoma line Daudi after exposure to n-butyrate and after EBV superinfection.

Authors:  B Contreras-Salazar; B Ehlin-Henriksson; G Klein; M G Masucci
Journal:  J Virol       Date:  1990-11       Impact factor: 5.103

8.  Human cytotoxic T-cell responses against Epstein-Barr virus nuclear antigens demonstrated by using recombinant vaccinia viruses.

Authors:  R J Murray; M G Kurilla; H M Griffin; J M Brooks; M Mackett; J R Arrand; M Rowe; S R Burrows; D J Moss; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

9.  Activation of latent EBV via anti-IgG-triggered, second messenger pathways in the Burkitt's lymphoma cell line Akata.

Authors:  M Daibata; R E Humphreys; K Takada; T Sairenji
Journal:  J Immunol       Date:  1990-06-15       Impact factor: 5.422

10.  Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1.

Authors:  F Wang; S F Tsang; M G Kurilla; J I Cohen; E Kieff
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

View more
  119 in total

1.  The Epstein-Barr virus latency BamHI-Q promoter is positively regulated by STATs and Zta interference with JAK/STAT activation leads to loss of BamHI-Q promoter activity.

Authors:  H Chen; J M Lee; Y Wang; D P Huang; R F Ambinder; S D Hayward
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

2.  Protein-DNA binding and CpG methylation at nucleotide resolution of latency-associated promoters Qp, Cp, and LMP1p of Epstein-Barr virus.

Authors:  D Salamon; M Takacs; D Ujvari; J Uhlig; H Wolf; J Minarovits; H H Niller
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

3.  Epstein-Barr virus (EBV)-negative B-lymphoma cell lines for clonal isolation and replication of EBV recombinants.

Authors:  A Marchini; R Longnecker; E Kieff
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

4.  The Epstein-Barr virus nuclear protein 1 promoter active in type I latency is autoregulated.

Authors:  J Sample; E B Henson; C Sample
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

5.  The Epstein-Barr virus (EBV) nuclear antigen 1 BamHI F promoter is activated on entry of EBV-transformed B cells into the lytic cycle.

Authors:  A L Lear; M Rowe; M G Kurilla; S Lee; S Henderson; E Kieff; A B Rickinson
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

6.  Promoter sequences required for reactivation of Epstein-Barr virus from latency.

Authors:  Ulrich K Binné; Wolfgang Amon; Paul J Farrell
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

7.  Interference with T cell receptor-HLA-DR interactions by Epstein-Barr virus gp42 results in reduced T helper cell recognition.

Authors:  Maaike E Ressing; Daphne van Leeuwen; Frank A W Verreck; Raquel Gomez; Bianca Heemskerk; Mireille Toebes; Maureen M Mullen; Theodore S Jardetzky; Richard Longnecker; Marco W Schilham; Tom H M Ottenhoff; Jacques Neefjes; Ton N Schumacher; Lindsey M Hutt-Fletcher; Emmanuel J H J Wiertz
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-22       Impact factor: 11.205

8.  Induction of Epstein-Barr virus latent membrane protein 1 by a lytic transactivator Rta.

Authors:  Yao Chang; Heng-Huan Lee; Shih-Shin Chang; Tsuey-Ying Hsu; Pei-Wen Wang; Yu-Sun Chang; Kenzo Takada; Ching-Hwa Tsai
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

9.  Epstein-barr virus-induced changes in B-lymphocyte gene expression.

Authors:  Kara L Carter; Ellen Cahir-McFarland; Elliott Kieff
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

10.  Redefining the Epstein-Barr virus-encoded nuclear antigen EBNA-1 gene promoter and transcription initiation site in group I Burkitt lymphoma cell lines.

Authors:  B C Schaefer; J L Strominger; S H Speck
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-07       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.